ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma

CAR-T Therapies Will Beat T-Cell Engagers To Market

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.

BCMA-targeting bispecifics are racing from Phase I into Phase II studies • Source: Shutterstock

There is no clear winner yet among bispecific antibodies targeting B-cell maturation antigen (BCMA) in the treatment of multiple myeloma, based on data presented virtually during the American Society of Hematology (ASH) annual meeting. However, these bispecifics are beginning to move into Phase II trials that may show whether they can compete with highly effective chimeric antigen receptor T-cell (CAR-T) therapies that likely will be the next BCMA-targeting modality to reach the market.

[Sidebar#SC143433]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D